Mechanisms of Anabolic Osteoporosis Therapy
Study Details
Study Description
Brief Summary
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
We will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks ("early") or 6-8 months ("late") after starting therapy. This is not a randomized clinical trial testing the efficacy of a drug - we will not be assigning volunteers to a specific osteoporosis therapy, though we will randomize volunteers to either the early or late second biopsy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Early Biopsy We will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks ("early") or 6-8 months ("late") after starting therapy. This is not a clinical trial: we will not be assigning volunteers to a specific osteoporosis therapy, though we will randomize volunteers to either the early or late second biopsy. |
Other: early versus late biopsy
early (3-6 weeks) versus late (6-8 months) biopsy
|
| Active Comparator: Late Biopsy We will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks ("early") or 6-8 months ("late") after starting therapy. This is not a clinical trial: we will not be assigning volunteers to a specific osteoporosis therapy, though we will randomize volunteers to either the early or late second biopsy. |
Other: early versus late biopsy
early (3-6 weeks) versus late (6-8 months) biopsy
|
Outcome Measures
Primary Outcome Measures
- Osteoblast progenitor cell numbers [3-6 weeks (early) versus 6-8 months (late)]
We are testing the mechanistic hypothesis that romosozumab treatment increases osteoblast progenitor cell numbers at early, but not late, treatment time points.
Eligibility Criteria
Criteria
Inclusion Criteria:
All postmenopausal women who are prescribed romosozumab by their treating physicians, meet the FDA-defined indication for romosozumab, and who are not at increased risk for a bone marrow aspirate or bone biopsy will be offered enrollment. The FDA approved indication for romosozumab is: "the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy." Volunteers must be:
-
Female aged > 45 years
-
Postmenopausal by either of the following criteria:
-
36 since last spontaneous menses
-
36 months since hysterectomy, plus serum FSH > 40 units / liter if < 60 years
Exclusion Criteria:
-
renal disease (stage 4 CKD)
-
elevated blood PTH (intact PTH > 77 pg/ml).
-
serum 25-OH vitamin D < 20 ng/ml
-
major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
-
excessive alcohol use or substance abuse that would preclude the subject from providing adequate informed consent or completing the protocol procedures.
-
known congenital or acquired bone disease other than osteoporosis.
-
exposure to oral bisphosphonates within the past 3 months, denosumab in the last 12 months, intravenous bisphosphonates within the past 24 months.
-
exposure to estrogens, SERMs, or calcitonin, oral or parenteral glucocorticoids for more than 14 days in the past 2 months.
-
any prior exposure to romosozumab.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Massachusetts General Hospital
Investigators
- Principal Investigator: Benjamin Leder, MD, Mass General Brigham
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1-P50-AR-080596-01